Form 4: Sera Prognostics Director Gregory Critchfield Receives Equity Grants

Sera Prognostics, Inc. Director Gregory C. Critchfield was granted 15,596 restricted stock units (RSUs) and 25,000 stock options as part of his compensation, vesting monthly over one year.

Summary

• Gregory C. Critchfield, a Director of Sera Prognostics, Inc. (SERA), acquired 15,596 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• These RSUs were granted at a price of $0 per share and will vest in monthly installments over one year, starting from June 5, 2025, contingent on his continued service to the issuer.
• Following this transaction, Mr. Critchfield beneficially owns 822,866 shares of Class A Common Stock directly.
• Additionally, Mr. Critchfield was granted 25,000 stock options on June 5, 2025, with an exercise price of $1.6 per share.
• These stock options were granted at a price of $0 and are exercisable from June 5, 2025, with an expiration date of June 5, 2035.
• The stock options also vest in monthly installments over one year, commencing June 5, 2025, and were issued under Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan.
• After this transaction, Mr. Critchfield directly beneficially owns 25,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it reflects standard compensation practices that align director interests with shareholder value, indicating continued commitment from a key board member. It is not a significant market-moving event but a routine positive for corporate governance.

Positives

• The grants of Restricted Stock Units (RSUs) and stock options align the director's interests with those of shareholders, as the value of these grants is tied to the company's stock performance.
• The vesting schedule, requiring continued service, incentivizes long-term commitment from the director.

Future Outlook

The document does not contain explicit forward-looking statements or guidance beyond the vesting schedules of the granted equity.

Industry Context

This filing is a routine disclosure of director compensation in the form of equity grants, common practice across various industries, including the biotechnology and diagnostics sector where Sera Prognostics operates. Such grants are standard mechanisms to attract and retain talent and align management incentives with shareholder value.

Comparison to Industry Standards

• The granting of RSUs and stock options as part of non-employee director compensation is a common practice in the biotechnology and healthcare industry, aligning with typical compensation structures for board members in publicly traded companies.
• The vesting schedule of 1/12 monthly over one year is a standard approach for equity compensation, similar to practices seen in companies like Exact Sciences Corp. (EXAS) or Guardant Health, Inc. (GH) for their non-executive directors, though specific grant sizes and exercise prices vary based on company size, performance, and compensation policies.

Related Party Transactions

• The transaction involves an equity grant to a director, which is a common form of compensation and a related-party transaction in the context of corporate governance.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's stock performance, potentially benefiting shareholders if the company's value increases.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect broader company policies on equity incentives.

Next Steps

• The Restricted Stock Units (RSUs) and stock options will vest in monthly installments over one year, commencing June 5, 2025, subject to Gregory C. Critchfield's continued service to Sera Prognostics, Inc.

Key Dates

Keywords

Sera Prognostics, SERA, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Grant, Director Compensation, Equity Incentive Plan